Dallas, Texas (PRWEB) October 17, 2014
This report provides comprehensive information on the therapeutic development for Osteoarthritis & Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis & Osteoporosis and special features on late-stage and discontinued projects.
Osteoarthritis – Pipeline Review, H2 2014
Osteoarthritis (OA) also known as degenerative arthritis or degenerative joint disease or osteoarthrosis, is a group of mechanical abnormalities involving degradation of joints, including articular cartilage and subchondral bone. Symptoms may include joint pain, tenderness, stiffness, locking, and sometimes an effusion. A variety of causes—hereditary, developmental, metabolic, and mechanical deficits—may initiate processes leading to loss of cartilage. When bone surfaces become less well protected by cartilage, bone may be exposed and damaged. As a result of decreased movement secondary to pain, regional muscles may atrophy, and ligaments may become more lax.
Treatment generally involves a combination of exercise, lifestyle modification, and analgesics. If pain becomes debilitating, joint replacement surgery may be used to improve the quality of life. OA is the most common form of arthritis, and the leading cause of chronic disability in the United States. It affects about 1.9 million people in Australia, 8 million people in the United Kingdom and nearly 27 million people in the United States.
Complete report available at http://www.rnrmarketresearch.com/osteoarthritis-pipeline-review-h2-2014-market-report.html . OR Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=231440 .
Osteoarthritis - Companies Involved in Therapeutics Development:
Seikagaku Corporation, Sanofi, Advanced Cell Technology, Inc., TiGenix NV, Novartis AG, Astellas Pharma Inc., Chong Kun Dang Pharmaceutical Corp., Teva Pharmaceutical Industries Limited, A. Menarini Industrie Farmaceutiche Riunite Srl, Merck KGaA, Bone Medical Limited, Addex Therapeutics Ltd, Can-Fite BioPharma Ltd., Medivir AB, Mesoblast Limited, Calzada Limited, NicOx S.A., Osteologix Holdings Plc., Yungjin Pharm Ind. Co., Ltd., Yuhan Corporation, Galapagos NV, CrystalGenomics, Inc., Biopharm GmbH, Upsher-Smith Laboratories, Inc., Abiogen Pharma S.p.A., Amura Holdings Ltd., PLx Pharma Inc., TissueGene, Inc., Rottapharm SpA, Cardax Pharmaceuticals, Inc., Nordic Bioscience a/s, Omeros Corporation, Cellceutix Corporation, Asklepios BioPharmaceutical, Inc., TOKUHON Corporation, K-Stemcell Co., Ltd., ReqMed Company, Ltd., Laila Pharmaceuticals Pvt. Ltd., Bioiberica, S.A., Stempeutics Research Private Limited, Ampio Pharmaceuticals, Inc., Arcarios BV, OrthoCyte Corporation, IntelliCell BioSciences Inc., Evgen Limited, AbbVie Inc., Genequine Biotherapeutics GmbH, Cellular Biomedicine Group, Inc., Voltarra Pharmaceuticals, Inc.
Osteoporosis – Pipeline Review, H2 2014
Osteoporosis is a progressive bone disease that is characterized by a decrease in bone mass and density which can lead to an increased risk of fracture. In osteoporosis, the bone mineral density (BMD) is reduced, bone microarchitecture deteriorates, and the amount and variety of proteins in bone are altered. Osteoporosis is defined by the World Health Organization (WHO) as a bone mineral density of 2.5 standard deviations or more below the mean peak bone mass (average of young, healthy adults) as measured by dual-energy X-ray absorptiometry; the term "established osteoporosis" includes the presence of a fragility fracture. The disease may be classified as primary type 1, primary type 2, or secondary. The form of osteoporosis most common in women after menopause is referred to as primary type 1 or postmenopausal osteoporosis. Primary type 2 osteoporosis or senile osteoporosis occurs after age 75 and is seen in both females and males at a ratio of 2:1. Secondary osteoporosis may arise at any age and affect men and women equally.
Complete report available at http://www.rnrmarketresearch.com/osteoporosis-pipeline-review-h2-2014-market-report.html . OR Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=231439 .
Osteoporosis - Companies Involved in Therapeutics Development:
F. Hoffmann-La Roche Ltd., Amgen Inc., Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Glide Pharmaceutical Technologies Limited, Novartis AG, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Zydus Cadila Healthcare Limited, Biodel Inc., Bone Medical Limited, Enzo Biochem, Inc., Kaken Pharmaceutical Co., Ltd., Lupin Limited, Medivir AB, Calzada Limited, Osteologix Holdings Plc., NeoStem, Inc., Dong Wha Pharma Co., Ltd., PhytoHealth Corporation, Galapagos NV, Uni-Bio Science Group Ltd., Oscotec Inc., Dongkook Pharmaceutical Co., Ltd., Merrion Pharmaceuticals Plc, Abiogen Pharma S.p.A., Ventria Bioscience, Critical Pharmaceuticals Limited, Alkem Laboratories Ltd., Amura Holdings Ltd., IMMD Inc., Alethia Biotherapeutics Inc., Kedem Pharmaceuticals Inc., Pantarhei Bioscience BV, Zealand Pharma A/S, Siena Biotech S.p.A., Omeros Corporation, Radius Health, Inc., EndoCeutics, Inc., Ensoltek Co., Ltd., TSRL, Inc., Pfenex Inc., Ausio Pharmaceuticals, LLC, Immunovo BV, ElexoPharm GmbH, Arcarios BV, Inbiopro Solutions Pvt. Ltd., Lead Discovery Center GmbH, Wroclawskie Centrum Badan EIT+ Sp. z o.o.
Browse more reports on Diseases & treatment Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment .
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.